Share price
₹2,596 latest close · +7.5% over the last 90 sessions
₹2,596 month-end · +14.0% over 12 months
₹2,596 month-end · +4.6% since Jun '25
52-week range ₹1733.00 to ₹3127.80 · 1-year volatility 43.6%
Was the rally earned?
Partly.
- Most of the rise came from investors paying a higher multiple (P/E 20.6x to 35.9x); per-share earnings took off 46 points.
- The share count barely moved.
What do "pts" mean?
"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.
Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.
Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.
Net profit is trailing twelve months as reported with a 60-day lag.
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-55.6% (2020-01 peak to 2020-03 low, recovered 2020-08)
-42.3% (2019-04 peak to 2019-08 low, recovered 2019-11)
-38.3% (2024-10 peak to 2026-03 low, recovered 2026-07)
Most recent volume spikes
2026-10-30: 8.7x the 50-day median, price -14.3% that day
2026-10-29: 8.6x the 50-day median, price +5.6% that day
2026-09-29: 6.8x the 50-day median, price +4.5% that day
Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE83rd
- Op. margin67th
- Revenue growth53rd
- EPS growth18th
- Debt/equity ↓80th▼ 18 pts vs a year ago
- Cash cycle ↓73rd▼ 5 pts vs a year ago
- P/E ↓53rd▼ 24 pts vs a year ago
- 12M momentum57th▼ 16 pts vs a year ago
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At a P/E of 35.9x, the price would imply about 20.7%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹2596.00
- P/E
- 35.9x
- ROCE
- 26.0%
- Market Cap
- ₹4293 cr
- Revenue (TTM)
- ₹735 cr
- P/S
- 5.8x
- P/B
- 7.1x
- ROE
- 19.7%
- Operating Margin
- 22.0%
- Debt / Equity
- 0.0x
- Promoter Holding
- 73.0%
- 12M Momentum
- 14.0%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance18%Near threshold
Other income as a share of pre-tax profit (trailing twelve months): 18.2%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate26%Within range
Median quarterly effective tax rate over about 2.5 years: 25.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow—Not enough data
Not enough reported data to compute this.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress—Not enough data
Not enough reported data to compute this.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Over 2 years, DIIs added 6.9 pts.
- The number of shareholders rose from 21,866 to 23,886 (+9%) between Dec 2023 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like RPG LIFE SCIENCES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −31% to +19% vs the market, against −6% for all non-financial companies in the same months.
- The gap against the base rate (−6.4%, 80% range −13.6% to +3.2%) is within what chance and overlapping periods produce.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 34 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| BLS Technology Services |
Nov 2024 | 45x | 31% | +47% | −15% | −18% |
| VESUVIUS Non-Energy Minerals |
Aug 2025 | 40x | 25% | −7% | −19% | −25% |
| JYOTHYLAB Consumer Non-Durables |
Jul 2024 | 52x | 27% | +69% | −4% | −33% |
| LAOPALA Consumer Durables |
May 2020 | 22x | 21% | −26% | −34% | +5% |
| DHANUKA Process Industries |
Feb 2020 | 20x | 23% | +16% | −14% | +14% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| TRITURBINE Producer Manufacturing |
Dec 2022 | 31x | 21% | +37% | −15% | +28% |
| SUMICHEM Process Industries |
Jun 2025 | 52x | 25% | +10% | −14% | −21% |
| ADVENZYMES Consumer Non-Durables |
Aug 2020 | 17x | 22% | +35% | −17% | +20% |
How reliable is this?
Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/S and 12-month momentum. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What else looks like this?
Companies with the most similar financial profile today, regardless of industry.
Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.
What changed?
30 events since Dec '20
- OctPriceVolume reached 8.7x its 50-day median on 2026-10-30; price -14.3% that day.
- JulPriceRegained the 2024-10 peak, 4 months after the low.
- JulPriceVolume reached 21.0x its 50-day median on 2026-07-10; price +7.5% that day.
- AprPriceVolume reached 207.5x its 50-day median on 2026-04-30; price +13.0% that day.
- MarPriceFell 38% from the Oct 2024 peak to the Mar 2026 low.
- JanPriceVolume reached 33.9x its 50-day median on 2026-01-28; price -6.7% that day.
- OctPriceVolume reached 30.6x its 50-day median on 2025-10-20; price +5.4% that day.
- JulPriceVolume reached 7.5x its 50-day median on 2025-07-28; price -9.9% that day.
Show 22 earlier events
- AprPriceVolume reached 32.5x its 50-day median on 2025-04-29; price +2.8% that day.
- JanPriceVolume reached 24.8x its 50-day median on 2025-01-27; price +9.0% that day.
- DecInstitutionsFII + DII holding rose 3.7 pts over 2 quarters to 6.8%.
- OctPriceVolume reached 10.1x its 50-day median on 2024-10-07; price +1.8% that day.
- JulPriceVolume reached 33.5x its 50-day median on 2024-07-22; price +3.0% that day.
- JunPriceVolume reached 7.7x its 50-day median on 2024-06-10; price +4.2% that day.
- MarPriceVolume reached 11.9x its 50-day median on 2024-03-06; price +3.2% that day.
- JulPriceRegained the 2022-11 peak, 4 months after the low.
- JulPriceVolume reached 8.4x its 50-day median on 2023-07-13; price +3.4% that day.
- JunPriceVolume reached 39.9x its 50-day median on 2023-06-09; price +11.4% that day.
- MarPriceFell 34% from the Nov 2022 peak to the Mar 2023 low.
- NovPriceVolume reached 11.7x its 50-day median on 2022-11-11; price +10.3% that day.
- AugPriceRegained the 2021-11 peak, 3 months after the low.
- AugPriceVolume reached 60.1x its 50-day median on 2022-08-03; price +10.2% that day.
- MayPriceFell 36% from the Nov 2021 peak to the May 2022 low.
- AprPriceVolume reached 7.7x its 50-day median on 2022-04-29; price +0.3% that day.
- MarPriceVolume reached 23.1x its 50-day median on 2022-03-21; price -2.1% that day.
- NovPriceVolume reached 5.1x its 50-day median on 2021-11-01; price +13.9% that day.
- SepPriceVolume reached 31.9x its 50-day median on 2021-09-01; price +13.7% that day.
- AprPriceVolume reached 48.7x its 50-day median on 2021-04-20; price +19.6% that day.
- JanPriceVolume reached 19.4x its 50-day median on 2021-01-20; price +9.9% that day.
- DecPriceVolume reached 6.3x its 50-day median on 2020-12-28; price +1.7% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history18 months · 2025-06 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 35.9x | ₹735 cr | 19.7% | 26.0% | 0.0x |
| 2026-10 | 35.7x | ₹735 cr | 19.8% | 26.0% | 0.0x |
| 2026-09 | 42.0x | ₹735 cr | 19.8% | 26.0% | 0.0x |
| 2026-08 | 37.8x | ₹708 cr | 19.0% | 26.0% | 0.0x |
| 2026-07 | 39.8x | ₹708 cr | 19.0% | 26.0% | 0.0x |
| 2026-06 | 32.9x | ₹708 cr | 19.0% | 26.0% | 0.0x |
| 2026-05 | 18.2x | ₹674 cr | 38.1% | — | 0.0x |
| 2026-04 | 18.7x | ₹674 cr | 38.1% | — | 0.0x |
| 2026-03 | 15.2x | ₹674 cr | 38.1% | — | 0.0x |
| 2026-02 | 14.4x | ₹667 cr | 40.6% | — | 0.0x |
| 2026-01 | 15.4x | ₹667 cr | 40.6% | — | 0.0x |
| 2025-12 | 17.8x | ₹667 cr | 40.6% | — | 0.0x |
| 2025-11 | 20.6x | ₹653 cr | 34.5% | — | 0.0x |
| 2025-10 | 21.7x | ₹653 cr | 34.5% | — | 0.0x |
| 2025-09 | 20.2x | ₹653 cr | 34.5% | — | 0.0x |
| 2025-08 | 20.9x | ₹653 cr | 34.5% | — | 0.0x |
| 2025-07 | 21.7x | ₹653 cr | 34.5% | — | 0.0x |
| 2025-06 | 22.4x | ₹653 cr | 34.5% | — | 0.0x |